Department of Orofacial Pain and Dysfunction, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, Gustav Mahlerlaan 3004, 1081 LA, Amsterdam, The Netherlands.
Department of Periodontology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Clin Rheumatol. 2021 Dec;40(12):4853-4860. doi: 10.1007/s10067-021-05860-y. Epub 2021 Jul 21.
To evaluate the effect of corticosteroid injections in the painful temporomandibular joint (TMJ) of patients with rheumatoid arthritis (RA) in relation to systemic inflammatory activity.
Examination of 35 patients (median age 54 years; 89% female) included maximum mouth opening capacity, degree of anterior open bite (AOB), TMJ pain intensity at rest, and crepitus. Serum levels of rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), serotonin, and plasma levels of interleukine-1β (IL-1β) were determined. Out of the 70 examined joints, 53 joints received a corticosteroid (methylprednisolone) injection after the clinical examination at baseline (T0). The examination was repeated for all patients at T1 (median 3.1 weeks after T0), and for 21 patients at T2 (median 6.3 weeks after T1), of whom 20 patients received a second injection at T1.
Maximum mouth opening capacity significantly increased, and TMJ pain intensity significantly decreased between T0 and T1, but these improvements were no longer present at T2. No differences were found in AOB between the time points. Of the joints that received an injection at T0, 19 joints had pretreatment crepitus, which resolved in eight joints at T1. No correlations were found between the change in mouth opening capacity or TMJ pain intensity and ESR, CRP, serotonin, or IL-1β.
Methylprednisolone injections in the TMJ alleviate pain and improve mouth opening capacity for approximately 3 weeks, allowing patients to perform jaw exercises during this timeframe of temporary relief. It thus seems useful for the short-term management of TMJ involvement in RA. Key Points • In rheumatoid arthritis, corticosteroid injection in the temporomandibular joint alleviates pain and improves function. • The clinical improvement achieved with methylprednisolone injections lasts for approximately 3 weeks. • Corticosteroid injections could be used to facilitate and support additional noninvasive, conservative treatment options.
评估皮质类固醇注射治疗类风湿关节炎(RA)患者颞下颌关节(TMJ)疼痛的效果与全身炎症活动的关系。
对 35 名患者(中位年龄 54 岁;89%为女性)进行检查,包括最大张口度、前开牙合度(AOB)、TMJ 静息疼痛强度和弹响。测定类风湿因子(RF)、红细胞沉降率(ESR)、C 反应蛋白(CRP)、血清 5-羟色胺和血浆白细胞介素-1β(IL-1β)水平。在 70 个检查关节中,53 个关节在基线时(T0)进行临床检查后接受皮质类固醇(甲泼尼龙)注射。所有患者在 T1(T0 后中位 3.1 周)时再次进行检查,21 名患者在 T2(T1 后中位 6.3 周)时再次进行检查,其中 20 名患者在 T1 时接受第二次注射。
T0 至 T1 时,最大张口度显著增加,TMJ 疼痛强度显著降低,但 T2 时这些改善不再存在。各时间点之间 AOB 无差异。在 T0 接受注射的关节中,19 个关节有治疗前弹响,在 T1 时有 8 个关节消失。张口度或 TMJ 疼痛强度的变化与 ESR、CRP、5-羟色胺或 IL-1β 之间无相关性。
TMJ 皮质类固醇注射可缓解疼痛并改善张口度约 3 周,使患者在这段临时缓解的时间内能够进行下颌运动。因此,它似乎对 RA 患者 TMJ 受累的短期管理有用。主要观点 • 在类风湿关节炎中,颞下颌关节皮质类固醇注射可缓解疼痛并改善功能。 • 甲泼尼龙注射的临床改善可持续约 3 周。 • 皮质类固醇注射可用于促进和支持其他非侵入性、保守的治疗选择。